Development of Prophylactic Therapy as a Preventative Strategy to Reduce COVID-19 Infections

引起冠状病毒引起的疾病（COVID-19）的SARS CoV-2的快速和渐进式传播深刻影响了全球数十万人的健康，使国家卫生保健系统紧张，并严重影响了全球经济稳定。SARS-CoV 2感染的机制是病毒与膜结合形式的血管紧张素转换酶2（ACE 2）的必要结合以及宿主细胞对复合物的内化。认识到ACE 2是冠状病毒的共受体，这为开发新的预防策略提供了机会，以阻断酶或减少其表达，从而防止细胞进入和SARS-CoV 2感染包括ACE 2表达的组织，如口腔，鼻腔，肺和肠上皮细胞。这些门户组织可能构成病毒进入宿主的最重要途径。我们将使用源自人类的口腔、气道和肠道组织的3D模型，评估针对ACE 2通道的新型预防性鼻腔和口服产品的作用机制。我们的目标是通过战略部署抗病毒鼻喷雾剂和漱口水/漱口水组合来预防或阻止冠状病毒感染，这些组合可以串联使用以预防COVID-19感染。我们打算产生关于使用我们两家合作公司提供的两种新技术的新知识（一氧化氮释放溶液NORS和高大麻二酚CBD提取物）;分别作为佐剂和协同作用，以开发一种新的预防性广谱抗菌策略来抑制SARS-CoV 2和其他类似的细菌或病毒感染。所产生的知识将有助于提供必要的科学支持，为我们的合作伙伴提供合成/制造策略所需的信息，以便为加拿大人开发急需的新型COVID-19预防解决方案。

The rapid and progressive spread of SARS CoV-2 that causes coronavirus-induced disease (COVID-19) has profoundly affected the health of hundreds of thousands of people around the world, strained national health care systems and significantly affected global economic stability. The mechanism of SARS-CoV2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the co-receptor for the coronavirus provides an opportunity to develop new preventative strategies to block the enzyme or reduce its expression to prevent cellular entry and SARS-CoV2 infection in tissues that include ACE2 expression such as oral, nasal, lung and intestinal epithelia. These gateway tissues likely constitute the most important routes of viral entry into the hosts. Using human derived 3D models of oral, airway and intestinal tissues, we will evaluate the mechanism of action of novel prophylactic nasa and oral products for humans which target ACE2 gateways. Our goal is to prevent or block coronavirus infection through the strategic deployment of an antiviral nasal spray and mouthwash/gargle combination that can be used in tandem prophylactically to prevent COVID-19 infection. We intend to generate new knowledge on the use of two new technologies provided by our two collaborating companies (Nitric Oxide Releasing Solution NORS and High-Cannabidiol CBD extracts); both separately and synergistically as adjuvants, in order to develop a new preventative broad spectrum anti-microbial strategy to inhibit SARS-CoV2 and other similar bacterial or viral infections. The knowledge generated will help provide the necessary scientific support required to inform the synthesis/manufacturing strategy for both of our collaborating partners in order to develop much needed novel preventative solutions to the COVID-19 epidemic for Canadians.